Damora Therapeutics Inc Ordinary Shares DMRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
-
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
-
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $21.71
- Day Range
- $20.46–21.53
- 52-Week Range
- $4.95–38.33
- Bid/Ask
- $8.52 / $28.50
- Shares Outstanding
- 61.74M
- Market Cap
- $1.30B
- Volume/Avg
- 359,785 / 525,947
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
- Website
- https://www.damoratx.com
Valuation
|
Metric
|
DMRA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.38 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
DMRA
Financial Strength
|
Metric
|
DMRA
|
|---|---|
Quick Ratio | 19.65 |
Current Ratio | 19.73 |
Interest Coverage | — |
Quick Ratio
DMRA
Profitability
|
Metric
|
DMRA
|
|---|---|
Return on Assets (Normalized) | −92.70% |
Return on Equity (Normalized) | −208.80% |
Return on Invested Capital (Normalized) | −101.41% |
Return on Assets
DMRA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Y<^lHNt | LOCK|?h!b> | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Q$bd#& | LOCK|@cWW@ | $83B | |||
| Moderna Inc
MRNA
| LOCK|&>m>!B< | LOCK|hHy | $80B | |||
| argenx SE ADR
ARGX
| LOCK|lTzcBZQ | LOCK|%>P | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Zj###W! | LOCK|^^ | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>@h<xG% | LOCK|GBrD | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>!VvsF!^ | LOCK|zH?n | $28B | |||
| Incyte Corp
INCY
| LOCK|?WvysBr | LOCK|F> | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|n>#&yn | LOCK|># | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|$p>YQc | LOCK|>V | $14B |
United States